About us
We are passionate about bringing the lab to the patient.
We are passionate about bringing the lab to the patient.
CEO
Wim van den Broek studied Bachelor Business Administration in Eindhoven and at the Webster University. From 1983 up to 1994 Wim van den Broek worked in several financial jobs in diverse branches. From 1995 until 2020 Wim van den Broek worked as CFO/CEO for TEGEMA, an engineering company located at the BRAINPORT region (Eindhoven). In this period TEGEMA changed from a mechanical engineering company to a multidisciplinary engineering company working for instance for STAGO in France and built a €10M prototype which was able to test blood on coagulation. This machine (ST GENESIA) is now used in hospitals all over the world. TEGEMA has been sold to ETTEPLAN in 2020 for strategic reasons. After that Wim van den Broek became a consultant and did interim work for several companies in the field of general management, strategy, finance , HRM and ICT. Wim van den Broek started December 1st 2024 for Enzyre.
CSO
Waander has over 30 years of experience as an expert in coagulation. He successfully founded and managed a spin-off company for 5 years and generated over €3M in contract research revenues for the Radboudumc. He was an inventor on 7 patent applications, and was part of over 80 scientific publications, inamongst others NEJM, Lancet and Blood. He is a former member of the International Society on Thrombosis and Hemostasis Standardization, Sub Committee “Fibrinolysis”, and a previous member of the scientific advisory board for the Dutch Thrombosis Foundation.
Director IVD Development
Rachel is an experienced product developer with a demonstrated history of working in the medical device industry. Skilled in assay development; from (pre)feasibility, through verification & validation (V&V) to the actual registration of a product. She loves to solve complex challenges in a creative, innovative and responsible way. After her PhD in Immunology at the Dutch Vaccine Institute (now part of the National Institute for Public Health and the Environment), she joined Organon / MSD and worked on the development of a small molecules-based medicine for the treatment of Rheumatoid Arthritis. At Organon, she valued the importance of quality during development. In 2015, she joined Future Diagnostics as a project leader focusing on assay development for third parties. She, successfully, helped developing the Minicare system of Siemens (formally Philips).
By bringing the lab to the patient, we can improve the quality of life without increasing healthcare costs.
Save patients from bleeding to death.
Develop a handheld device that can run multiple assays in parallel to identify the cause of a bleed so therapy can be adjusted without delay.
Our team of experts is innovating near patient diagnostics with a focus on blood coagulation.
Enzyre is always looking for collaborations to expand use of its platform technologies. Interested parties are encouraged to contact us at info@enzyre.com.
Get involved
Enzyre BV
Transistorweg 5
6534-AT Nijmegen
The Netherlands
